Given the potential diversity of CAR T therapies and the ongoing evolution of patient-reported outcome (PRO) tools, Medicare should not require the use of PROs in making coverage determinations for new gene therapies, several experts told the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) Wednesday.